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  Introduction to Practice Inquiry Project 
The introduction of chemotherapy in pediatric oncology tremendously impacted the 
survival of children with cancer. In the past 60 years, the survival rates of children with cancer 
have drastically improved with 5-year survival rates of the most common types of childhood 
cancer nearing 90%. Use of chemotherapeutic agents is not without risk as they are administered 
in a variety of routes and doses. Disturbingly high error rate ranging from 4% to 18%, depending upon 
the administration setting (inpatient or outpatient) are reported in the literature (Watts & Parsons, 2013).  
Chemotherapy errors have the potential to be lethal because of a low therapeutic index 
and the lack of an antidote to reverse potential toxicities associated with chemotherapy errors. 
Guidelines for safe administration of chemotherapy have been published by the Oncology 
Nursing Society and the American Society of Health-Systems Pharmacists; however, the 
Association of Pediatric Hematology and Oncology Nurses (APHON) recognized the need for 
tailored guidelines for the pediatric oncology patient population. In 2004, APHON introduced 
the Pediatric Chemotherapy and Biotherapy Provider Program with the goal of giving nurses the 
knowledge needed to safely and consistently administer chemotherapy and biotherapy. Since its 
inception, the APHON chemotherapy and biotherapy program has become the national standard 
for teaching nurses how to administer chemotherapy and biotherapy to children and adolescents 
(Kline, 2007). 
The overall purpose of this practice inquiry project is to assess knowledge, beliefs and the 
impact nursing has had on chemotherapy/biotherapy administration one year post 
implementation of the APHON Chemotherapy/Biotherapy Provider Program in a children’s 
hospital located within a large medical teaching facility. The first manuscript is a review of 
articles published between 2005 and 2015 regarding methods/procedures used to ensure safe 
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chemotherapy administration to oncology patients. The findings from this review provided 
evidence to support a planned change in chemotherapy administration curriculum for pediatric 
oncology nurses in a children’s hospital. Strategies suggested for standardizing administration of 
chemotherapy included adoption of clinical guidelines or curriculum set forth by professional 
organizations including the American Society of Clinical Oncology (ASCO), the Oncology 
Nursing Society (ONS), as well as the Association of Pediatric Hematology and Oncology 
Nurses (APHON) (Jacobson, et al., 2009; Kline, 2007; Neuss, Polovich, McNiff, Esper, Gilmore, 
LeFebvre, Schulmeister, & Jacobson, 2013).  
The second manuscript is a microsystem level analysis on the implementation of the 
APHON program and discusses the importance of following a change theory to successfully 
implement a planned change. It focuses on the importance of having a purposeful, collaborative 
plan as well as support on multiple system levels, and by-in from those affected by change in 
order to achieve successful plan implementation. Continuous process improvement in addition to 
provision of feedback related to performance and outcomes were also identified as factors 
influencing a planned change that endures.  
The final manuscript describes an analysis performed to determine the knowledge base 
and beliefs of nurses regarding administration of chemotherapy/biotherapy to pediatric oncology 
patients one year post implementation of the APHON chemotherapy/biotherapy course. 
Additionally, the researcher was interested in the nurses’ beliefs regarding the impact of nursing 
on safe administration of chemotherapy/biotherapy to pediatric oncology patients. 
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Abstract 
The advent and use of chemotherapy tremendously impacted the survival of children with 
cancer. In the past 60 years, the survival rates of children with cancer have drastically improved 
with 5-year survival rates of the most common types of childhood cancer nearing 90%. Use of 
chemotherapeutic agents is not without risk as they are administered in a variety of routes and 
doses. It is important for nurses to have the knowledge needed to safely administer antineoplastic 
agents to all patients, but in particular pediatric oncology patients. The goal of this article is to 
review the policies and practices used in facilities across the country to ensure chemotherapy and 
biotherapy are administered safely at all times.  
 Keywords:  safe chemotherapy administration, guidelines, practices, oncology, pediatric 
oncology, nursing competence 
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Safe Administration of Chemotherapy for the Pediatric Oncology Patient:   
A Review of Literature 
 Childhood cancer will affect 1 in every 285 children in the United States before they turn 
20 years old and accounts for more disease related deaths in children than AIDS, asthma, cystic 
fibrosis, diabetes and congenital anomalies combined. Fortunately, medical advances over the 
last sixty years have improved survival rates and nearly 90% of children with the most common 
types of cancer will have at least a 5-year event-free survival (St. Baldrick’s Foundation, 2014). 
The use of antineoplastic chemotherapy agents in particular, has tremendously improved survival 
rates for children with childhood cancer; however, they are not used without risk and they top the 
list of high-alert medications according to the Institute for Safe Medication Practices (2003). 
Because of their low therapeutic index and narrow safety margins, chemotherapy agents have the 
potential to cause catastrophic harm if administration error occurred. Studies in pediatric 
oncology suggest a disturbingly high error rate ranging from 4% to 18%, depending upon the 
administration setting (inpatient or outpatient) (Watts & Parsons, 2013).  
Complex treatment protocols including multidrug regimens, multiple routes of 
administration, as well as a variety of dosages based on the administration route (e.g. 
intravenous, intrathecal, oral, subcutaneous, intramuscular) further potentiates the risk for 
administration error (Sheridan-Leos, 2007). Previously researchers have recognized that 
chemotherapy errors can occur anywhere along the process, from prescribing, mixing, dispensing 
and administration (Sheridan-Leos, 2007; Vioral & Kennihan, 2012); however, recently 
researchers suggest that administration errors are most common (Dhamija, Kapoor, & Juneja, 
2014). Due to the complex nature of chemotherapy administration, it is necessary to have in 
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place standardized chemotherapy administration protocols as well as education for nurses to 
ensure the safety of all patients.  
 The purpose of this review is to explore current guidelines and procedures used by 
organizations around the US to ensure the safety of patients and staff regarding administration of 
chemotherapy in order to reduce the risk of chemotherapy administration error.  
Literature Review 
Systematic Approach 
 The U.S. National Library of Medicine National Institutes of Health (PubMed) and 
Cumulative Index to Nursing and Allied Health Literature (CINAHL) electronic databases were 
searched for pertinent articles published between 2005 and 2015. Articles were chosen if they 
were printed in English and discussed methods/procedures used to ensure safe chemotherapy 
administration to oncology patients. Articles focusing on chemotherapy order entry and 
dispensing were excluded from the review. Keywords used:  safe chemotherapy administration, 
guidelines, practices, oncology, pediatric oncology, nursing competence. 
 Nine articles met the inclusion criteria for the review including: one descriptive study, 
two practice guidelines, and six case reports. 
Summary of Evidence 
 Recommendations for avoiding chemotherapy administration errors and improving 
patient safety call for standardized approaches to administering chemotherapy in in- and 
outpatient settings as well as development or revision of policies and procedures for system 
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improvement (Jacobson, Polovich, McNiff, LeFebvre, Cummings, Galioto, Bonelli, & 
McCorkle, 2009). Strategies suggested for standardizing administration of chemotherapy 
included adoption of clinical guidelines or curriculum set forth by professional organizations 
including the American Society of Clinical Oncology (ASCO), the Oncology Nursing Society 
(ONS), as well as the Association of Pediatric Hematology and Oncology Nurses (APHON) 
(Jacobson, et al., 2009; Kline, 2007; Neuss, Polovich, McNiff, Esper, Gilmore, LeFebvre, 
Schulmeister, & Jacobson, 2013). The literature supports the use of standardized didactic 
curriculum for nurses in addition to simulations involving patients receiving chemotherapy 
(Andam & Silva, 2008; Linnard-Palmer, 2012; Vioral & Kennihan, 2012). Clinical guidelines 
established by the ASCO, ONS, and APHON have been used since the mid-2000’s and are 
recognized as standards of care for administering chemotherapy to oncology patients. The 
guidelines address topics related to treatment regimens and plans, drug preparation, supportive 
care measures, as well as management of drug toxicities (Kline, 2007; Vioral & Kennihan, 2012; 
Weingart, Li, Zhu, Morway, Stuver, Shulman, & Hassett, 2012). 
 Use of a multidisciplinary approach in order to create a culture of safety surrounding 
administration of chemotherapy was another common theme derived from the literature. The 
literature supports implementation of a multiple check/verification system of chemotherapy by at 
least two RNs prior to administration. An additional verification of the chemotherapeutic agent 
by a pharmacist is advised in multiple reports (Neuss et al., 2013; Robinson, Heigham, & Clark, 
2006; Sheridan-Leos, 2007; Vioral & Kennihan, 2012). 
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Methods 
 The first set of practice guidelines used in this review was developed by the ASCO and 
the ONS and includes a list of 31 standards developed by a multidisciplinary steering group. The 
two professional groups recognized a need for a set of national standards regarding 
administration of chemotherapy in response to reports of chemotherapy administration errors. 
The ASCO and ONS standards for safe chemotherapy administration provide a framework for 
best practice and should be a goal for oncology care providers (Jacobson et al., 2009). In 2013, 
the ASCO and ONS updated their chemotherapy administration standards in response to 
increasing use of oral chemotherapy agents. Once again, a multidisciplinary steering group met 
to address concerns related to administration of oral agents and additional standards were 
developed. The new standards focus on importance of patient and family education regarding at-
home administration schedules, how to store and dispose of oral chemotherapy agents, and the 
importance of monitoring and assessing for toxicities associated with oral agents (Neuss et al., 
2013).  
The majority of articles used in this review were case reports from institutions across the 
country regarding implementation of standards set forth by professional organizations. Vioral 
and Kennihan (2012) and Sheridan-Leos (2007) describe implementation of chemotherapy 
administration standards at large, suburban hospitals using a multidisciplinary approach. In both 
reports, organizers of change engaged members of multiple disciplines including nursing, 
medicine, pharmacy, administration and management to ensure successful implementation of 
new standards.  
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Andam and Silva (2008), Linnard-Palmer (2012), and Robinson et al. (2006) discussed 
methods employed to improve safety of chemotherapy administration to pediatric oncology 
patients. Andam and Silva (2008) used adult ONS chemotherapy administration guidelines and 
tailored them to the pediatric setting in a large urban children’s hospital, while Linnard-Palmer 
(2012) used a combination of simulation scenarios and didactic education to ensure staff nurses 
as well as BSN nursing students in a teaching children’s hospital were able to apply essential 
safety components of care to the child with cancer. Finally, Robinson et al. (2006) used a 
multidisciplinary approach to identify potential weaknesses in the chemotherapy administration 
process using the Failure Mode Effects Analysis (FMEA) at a large urban children’s hospital. 
Following implementation of FMEA, a retrospective chart review of 221 charts over a three year 
span indicated that a 25% decrease in the number of administration errors.  
Weingart et al. (2012) sought to assess the number of National Cancer Institute (NCI)-
designated centers that had implemented the ASCO/ONC chemotherapy administration safety 
standards. Through a series of surveys, the researchers determined that more than half of the 
NCI-designated centers (n=31) had fully implemented that chemotherapy administration 
standards. 
Strengths, Limitations and Gaps 
 The published guidelines from ASCO/ONS are thorough in nature and were developed 
by members of multiple disciplines. The latest updates address the fact that many of the newer 
chemotherapy agents can be given in oral form, on an outpatient basis. Researchers suggest the 
majority of cancer centers across the country have adopted the standards of care to guide in safe 
administration of chemotherapy and that institutions have recognized the need for 
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standardization in chemotherapy administration in order to ensure patient safety. Researchers 
further suggest reasons for non-adoption of the standards could be due to lack of resources 
including personnel and funding (Weingart et al., 2012).  
The articles reviewed in this study were descriptive in nature and include practice 
guidelines which are lower levels of evidence (levels IV and V) according to Johns Hopkins 
Nursing Levels of Evidence (2012). The review may have been strengthened had there been 
published articles with higher levels of evidence including randomized controlled trials (RCTs) 
or systematic reviews of RCTs. While there are a number of reports documenting 
implementation of the standards in adult oncology settings, there is little literature pertaining to 
safe administration of chemotherapy in the pediatric oncology setting. Kline (2007) discusses 
development of the APHON Chemotherapy/Biotherapy Provider Course; however, there are no 
published reports on how this has affected patient outcomes in terms of reducing the number of 
chemotherapy administration errors or how the course has impacted nursing.  
Implications for Practice 
 Policies need to address safe administration of chemotherapy and nurses need to be 
provided the knowledge to safely administer chemotherapy in order to ensure high-quality 
outcomes for patients (Vioral & Kennihan, 2012). The literature supports the use of a number of 
methods to ensure safety is a priority for patients and staff alike during the chemotherapy 
process. The strategies employed by Andam and Silva (2008) and Kline (2007) use a 
standardized curriculum to ensure nurses have the knowledge base and background needed to 
safely administer chemotherapy and biotherapy to patients. The APHON curriculum is specific 
to the pediatric oncology patient and addresses topics such as toxicity and symptom management 
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as well as psychosocial needs of the pediatric oncology patient. These topics were not covered by 
the ONS curriculum; however, nurses who completed evaluations for the ONS course expressed 
a need for pediatric-specific education (Andam & Silva, 2008). The multimodal system of 
learning used by Linnard-Palmer (2012) was embraced by participants who felt they attained a 
high level of skills through the patient simulation experience. Perhaps a simulation experience 
coupled with APHON’s pediatric-specific didactic curriculum would offer nurses a 
comprehensive overview of how to safely administer chemotherapy and biotherapy to the 
pediatric oncology patient.  
 The other methods described in the literature as being successful involve forming a 
multidisciplinary team to evaluate and improve the chemotherapy process and implementation of 
template order sets.  Common themes arise in the articles by Sheridan-Leos (2007), Robinson, 
Heigham, and Clark (2006), and Vioral and Kennihan (2012) including use of a proactive 
approach to identify weaknesses in a system before a catastrophic error occurs and importance of 
buy-in from all disciplines to improve a system with a high-risk for error.  
Conclusion and Recommendation for Future Study 
 Institutions across the country have recognized the need to improve the system of 
chemotherapy administration. Administration of chemotherapy and biotherapy to a vulnerable 
population is a high-stakes process. The smallest error can lead to irreversible damage, and 
possibly death. A combination of the methods discussed in this review seems to be the best way 
to ensure the safety of the pediatric oncology patient. As a DNP prepared nurse, it is important to 
have a pulse on the learning needs of staff nurses and to advocate for opportunities for education 
and enrichment for those on the front-line regarding patient care. It is also important to recognize 
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the importance of the multidisciplinary team when evaluating the chemotherapy process. Each 
discipline plays a vital role in ensuring the safety of the pediatric oncology patient, serving as a 
checks-and-balance system to guarantee accuracy in all chemotherapy orders. 
 Future research may focus on qualifying the nurses’ experience following completion and 
implementation of the APHON chemotherapy/biotherapy provider program. Additional research 
may also include measuring the cost savings a proactive approach to the chemotherapy process, 
or identification of weaknesses in the current chemotherapy administration process would incur.  
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The Division of Pediatric Hematology/Oncology at the University of Kentucky in 
conjunction with Kentucky Children’s Hospital recently revised the practice for educating nurses 
on safe administration of chemotherapy and biotherapy to pediatric oncology patients. This paper 
will discuss reasons behind the change as well as implementation and analysis on a microsystem 
level.   
Background 
The Institute of Medicine (IOM) (2000) reports approximately 7,000 deaths per year are 
related to medication error. Pediatric cancer patients experience fewer medication errors than 
other populations; however, when chemotherapy errors do occur, they generally have devastating 
effects (Sheridan-Leos, 2007). In a 2003 survey of nurses and pharmacists conducted by the 
IOM, chemotherapy ranked first in a list of high-alert medications. Survey participants perceived 
chemotherapy errors to have a higher risk of causing significant harm to patients than errors 
involving IV potassium chloride and insulin (IOM, 2003). Chemotherapy errors have the 
potential to be lethal because of a low therapeutic index and the lack of an antidote to reverse 
potential toxicities associated with chemotherapy errors.  
Guidelines for safe administration of chemotherapy have been published by the Oncology 
Nursing Society and the American Society of Health-Systems Pharmacists; however, the 
Association of Pediatric Hematology and Oncology Nurses (APHON) recognized the need for 
tailored guidelines for the pediatric oncology patient population. In 2004, APHON introduced 
the Pediatric Chemotherapy and Biotherapy Provider Program with the goal of giving nurses the 
knowledge needed to safely and consistently administer chemotherapy and biotherapy. Since its 
inception, the APHON chemotherapy and biotherapy program has become the national standard 
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for teaching nurses how to administer chemotherapy and biotherapy to children and adolescents 
(Kline, 2007). 
Prior to implementation of the APHON program, nurses at KCH attended a 
“homegrown” chemotherapy administration course. While this course was informative and 
nurses were considered competent to administer chemotherapy following its completion, it was 
not the method for teaching safe administration of chemotherapy and biotherapy to pediatric 
oncology patients employed at benchmark institutions around the country. Implementation of the 
APHON program not only gives nurse at KCH the most current information regarding safe, 
consistent administration of chemotherapy and biotherapy, it gives them the opportunity to gain 
APHON provider status, the national standard for administration of chemotherapy and 
biotherapy to pediatric oncology patients. 
Plan and Implementation 
Program 
  Implementation of the Association of Pediatric Hematology/Oncology Nurses (APHON) 
chemotherapy and biotherapy provider program began in October of 2013 at Kentucky 
Children’s Hospital (KCH) so nurses would have the same knowledge base pertaining to 
pediatric chemotherapy and biotherapy as nurses in benchmark institutions around the country. 
As of April 2014, all current nursing staff who administer chemotherapy and biotherapy to 
pediatric oncology patients in KCH had successfully completed the APHON course.  
The APHON Pediatric Chemotherapy and Biotherapy Provider Program is comprised of 
two 8-hour days of didactic teaching covering content related to differences between pediatric 
and adult cancers, clinical trials, administration of chemotherapy and biotherapy agents, side 
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effects, toxicity and symptom management, psychosocial issues, as well as legal and ethical 
issues. The course is co-taught in a classroom in KCH by two APRNs and two RNs (BSN). 
Following course completion, participants must pass a fifty question computerized test 
administered through the APHON website. A score of 80% or higher must be achieved in order 
for participants to achieve “provider status.” All participants get to keep their text from the 
course and receive 13.75 CEUs for participation. Participants are also compensated for their time 
as they receive professional development pay for time spent in the APHON course. 
Identification of Microsystem 
 The structure of a health care system includes a macrosystem which encompasses a 
system as a whole, multiple microsystems composed of front-line clinical units, and patient 
subpopulations in need of individualized care. The microsystem in this instance is the division of 
pediatric hematology/oncology, specifically nurses who administer chemotherapy to pediatric 
oncology patients. This microsystem is part of a large medical teaching facility (macrosystem). 
Microsystems are comprised of clinicians and support staff who work to meet patients’ needs 
providing direct care, accessing systems, assessing patient and staff needs, establishing treatment 
plans, and evaluating outcomes over time (Nelson, Batalden, Huber, Mohr, Godfrey, Headrick, 
& Wasson, 2002). The advanced practice nurses and nurse coordinators within the division of 
pediatric hematology/oncology recognized a need to improve the knowledge base of front-line 
nurses responsible for administering chemotherapy to pediatric oncology patients. In order to 
expand the knowledge base and bring the teaching up to par with national standards, the group of 
nurses planned to implement the APHON Chemotherapy/Biotherapy Provider course so nurses 
would have the same knowledge base pertaining to pediatric chemotherapy and biotherapy as 
their peers across the country. 
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Major Stakeholders 
 Stakeholders involved in implementing the APHON Chemotherapy/Biotherapy Provider 
program include:  advanced practice nurses (APRNs), staff nurses, nursing staff development, 
nurse managers, nursing administration, physicians, patients, and the healthcare facility. 
Change Theory 
 In order to successfully implement the APHON Chemotherapy/Biotherapy Provider 
program, stakeholders needed to identify a change theory best suited to implement the planned 
change. Kurt Lewin identified three stages through which stakeholders must progress in order for 
change to become part of a system. Those stages include unfreezing, moving, and refreezing 
(Mitchell, 2013). 
 During the unfreezing phase, the APRNs and nurse coordinators examined the status quo 
regarding what staff nurses were being taught regarding safe administration of chemotherapy and 
biotherapy agents to pediatric oncology patients. This group of nurses determined that most 
pediatric oncology centers around the country had implemented the APHON 
Chemotherapy/Biotherapy Provider Program as a way of preparing their nurses to safely 
administer these agents to pediatric patients. The APRNs and nurse coordinators proposed the 
idea of implementing the APHON program to pediatric nursing administration, staff 
development, and the division chief for pediatric hematology/oncology. The proposal was made 
during a time of change in leadership in both nursing administration as well as within the 
division of pediatric hematology/oncology. Fortunately the new leaders fostered a sense of 
empowerment for nurses and the idea of expanding the knowledge base of nurses to ultimately 
improve the quality of care was embraced by nursing administration as well the division chief. 
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Furthermore, the chief of pediatric hematology/oncology approved the use of division funds to 
pay for the program.  
 Moving forward, the APRNs and nurse coordinators met regularly to determine when 
implementation would begin, how often they would teach the course in order to ensure all 
current staff as well as newly-hired staff had the opportunity to attend, and how many nurses 
should attend each course at a particular time. With the help of the pediatric acute care nurse 
manager, the group of nurses assigned all current staff as well as newly-hired staff (based on 
order of hire) a date to attending the two-day APHON program. Implementation began in 
October of 2013 and all current staff had successfully completed the program as of April 2014. 
Additional classes are now held on a quarterly basis for newly-hired RNs.  
 The division is currently in the refreezing phase or a phase of adoption and evaluation. 
The APHON program has been established and the new standard for teaching nurses how to 
safely administer chemotherapy and biotherapy to pediatric oncology patients. The APRNs, 
nurse coordinators, physicians and nursing administration are providing ongoing support to the 
front-line RNs administering chemotherapy on a daily basis. Stakeholders continue to evaluate 
the program to determine the knowledge base and beliefs of nurses regarding administration of 
chemotherapy/biotherapy to pediatric oncology patients one year post implementation of the 
APHON chemotherapy/biotherapy course. Additionally, stakeholders are interested in nurses’ 
beliefs regarding the impact of nursing on safe administration of chemotherapy/biotherapy to 
pediatric oncology patients. 
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Analysis and Outcome 
The APRNs and the nurse coordinators were the driving forces behind change in this 
situation; however, implementation of the APHON program would not have been successful 
without support from leaders in the microsystem as well as macrosystem. Mohr and Donaldson 
(2000) describe a high-quality microsystem as having the following characteristics:  willingness 
to invest in improvement, training that provides for efficiency and staff satisfaction, 
interdependence of a care team whose goal is to meet patient needs, integration of information 
into work flow, ongoing outcomes analysis, and support from the larger organization 
(macrosystem). The leaders on a microsystem level were willing to invest in a program to give 
nurses the knowledge needed to safely administer chemotherapy to pediatric oncology patients, 
educate patients and families on treatment plans, and know that it is acceptable to ask questions 
of providers regarding treatment regimens. It is the hope of the APRNs and nurse coordinators 
who led the change that nurses will be able to integrate knowledge learned in the APHON 
program into daily practice.  
Continuous process improvement is also a characteristic of a high-quality microsystem. 
In order to get a true measurement of how implementation of the APHON 
Chemotherapy/Biotherapy Provider Program has impacted nursing it will be important to gather 
feedback from the staff nurses. Under the current division chief, the microsystem has sought to 
empower nurses in hopes of encouraging a sense of ownership in the program. A sense of 
ownership in the program may foster a higher rate of fidelity regarding implementation of the 
principles learned in the APHON course.    
Since implantation of the APHON program in October of 2013, fifty nurses have 
successfully completed the curriculum. The APHON program is now the required course for all 
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nurses who administer chemotherapy and biotherapy to pediatric oncology patients at Kentucky 
Children’s Hospital. Nurses who currently hold the APHON Chemotherapy/Biotherapy Provider 
status must renew their credentials every two years by taking an online review course 
administered through APHON’s website. Nurses who are newly hired must complete the 
APHON course within six months of their hire date in order to be able to administer 
chemotherapy to pediatric oncology patients.  
Recommendations for Improving the Change Process 
 The APRNs and nurse coordinators proposed implementation of the APHON program in 
a climate that was open to change. The plan was well thought and purposeful and impacted both 
staff and patients. Retrospectively, it would have been ideal to have included a few staff nurses 
in the planning phase and proposal of the program to ensure members of all areas affected had a 
voice in the proposed plan. Fortunately, the staff nurses welcomed the opportunity to build on 
the knowledge they already possessed and embraced the change without resistance.  
Feedback related to performance and outcomes, as well as, opportunities for the staff to 
discuss barriers to the process as well as how the program has impacted how they provide 
nursing care should be provided.  Staff should be recognized for achieving targeted outcomes to 
help solidify the new practice.  Ongoing monitoring and feedback will be critical to the long-
term success of the APHON program.  
Nursing Implications 
 Because of its high-alert status, it is imperative that all nurses who administer 
chemotherapy and biotherapy to pediatric oncology patients have the knowledge base needed to 
ensure safe administration with every patient, every time so potentially harmful errors can be 
avoided. Successful completion of the APHON Chemotherapy/Biotherapy provider course 
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ensures nurses are equipped with the knowledge and could serve as a stepping stone for nurses to 
pursue specialty certification through the Oncology Nursing Society (ONS) as a Certified 
Pediatric Hematology Oncology Nurse (CPHON). 
 The literature acknowledges the importance of adherence to guidelines when 
administering chemotherapy and biotherapy to pediatric oncology patients. However, since 
implementation of the APHON Pediatric Chemotherapy and Biotherapy Provider Program in 
2004, there have been no published articles on the knowledge base of nurses following 
successful completion of the APHON program. Future research could focus on the relationship 
between successful completion of the APHON program and pursuit of specialty certification. 
Conclusion 
 Implementing change is not an easy task. It is necessary to have a purposeful plan that is 
calculated and collaborative in nature. Identification of an appropriate change theory can be 
useful to ensure the planned change is accepted and endures. Support on multiple system levels 
as well as by-in from those affected by change are also critical components to successful plan 
implementation. Continuous process improvement that is patient and staff focused, empowering 
staff to share ideas and innovations, and providing continuous feedback regarding progress are 
all necessary in order for a plan to be successful and sustained.  
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Abstract 
Aim:  The purpose of this study is to assess nurses’ knowledge and beliefs related to 
chemotherapy/biotherapy administration in the pediatric oncology population at least one year 
post implementation of the APHON chemotherapy/biotherapy provider course. Specifically, the 
principal investigator is interested in knowing if nurses feel they have been able to use the 
knowledge gained in the APHON course to positively impact the pediatric oncology patient.  
Design:  A descriptive design was used to describe associations between nurses’ knowledge and 
beliefs regarding safe administration of chemotherapy/biotherapy to pediatric oncology patients. 
An invitation to a 26 item questionnaire, administered via Qualtrics was sent via secure email to 
all pediatric hematology/oncology nurses (inpatient and outpatient) who completed the APHON 
chemotherapy/biotherapy provider course as of April 2014. 
Setting:  A children’s hospital within a large medical teaching facility including an ambulatory 
care clinic. 
Participants: The study was open to all 35 registered nurses at the University of Kentucky (all at 
least 18 years of age) who had completed the APHON chemotherapy/biotherapy provider course 
as of April 2014.   
Outcome Measure:  Pediatric oncology nurses’ knowledge of and confidence in administration 
of chemotherapy. Data were also analyzed to determine if there is a statistically significant 
difference between groups of nurses.  
Results:  Overall, participants reported a high level of knowledge regarding administration of 
chemotherapy/biotherapy to pediatric oncology patients; however, there were no significant 
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differences found in relation to total knowledge scores with age, education level, or with how 
long the participant has been an APHON provider.  
Conclusion:  Evaluation of the APHON chemotherapy/biotherapy program at least one year post 
participants’ completion revealed high scores related to knowledge regarding safe administration 
of neoplastic agents to pediatric oncology patients.  
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Introduction 
 In 2015, approximately 10,400 children in the US under the age of 15 will be diagnosed 
with cancer. The introduction of multiple agent regimens of chemotherapy in the 1970’s 
drastically improved the 5-year survival rate for pediatric oncology patients. Today, nearly 90% 
of children diagnosed with cancer will survive 5 years or more, compared to only 58% in the 
mid-1970’s (American Cancer Society, 2015). Administration of chemotherapy is not without 
risk. Studies in pediatric oncology suggest a disturbingly high error rate ranging from 4% to 
18%, and may cause devastating, if not lethal effects (Watts & Parsons, 2013). 
Recommendations for avoiding chemotherapy administration errors and improving 
patient safety call for standardized approaches to administering chemotherapy in inpatient and 
outpatient settings as well as development or revision of policies and procedures for system 
improvement (Jacobson, Polovich, McNiff, LeFebvre, Cummings, Galioto, Bonelli, & 
McCorkle, 2009). In 2004, the Association of Pediatric Hematology and Oncology Nurses 
(APHON) introduced the Pediatric Chemotherapy and Biotherapy Provider Program. The 
intensive, two day, didactic program is intended to give nurses the knowledge needed to safely 
and consistently administer chemotherapy and biotherapy. Since its inception, the APHON 
chemotherapy and biotherapy program has become the national standard for teaching nurses how 
to administer chemotherapy and biotherapy to children and adolescents; however, since 
implementation of the standards, there have been no published reports on patient outcomes in 
terms of reducing the number of chemotherapy administration errors or how the course has 
impacted nursing (Kline, 2007).  
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Implementation of the APHON chemotherapy and biotherapy provider program began in 
October of 2013 at Kentucky Children’s Hospital (KCH) and as of April 2014, all current 
nursing staff who administer chemotherapy and biotherapy to pediatric oncology patients in 
KCH had successfully completed the APHON course. The purpose of this program evaluation 
was to assess knowledge, beliefs and the impact nursing has had on chemotherapy/biotherapy 
administration one year post implementation of the APHON program.  
Methods 
The study took place in a children’s hospital located within a large medical teaching 
facility and was approved by the University of Kentucky Institutional Review Board (UK IRB). 
The principal investigator (PI) was an instructor for the APHON course at the university and had 
access to participants’ email addresses. Potential subjects had to be 18 years of age and had to 
have successfully completed the course by April 2014. Thirty-five potential subjects were 
identified as meeting these criteria and were sent an invitation via secure email to participate in 
an online survey. Subjects’ identities were not linked to the survey as the invitation email to the 
survey contained an anonymous link to the Qualtrics survey. Qualtrics is a secure web-based 
application used to build and manage online surveys and databases. All data collected using 
Qualtrics are housed on secure servers and can be exported to various statistical software. No 
identifying information was tied to participants’ responses.  
Data Collection 
The principal investigator (PI) sent an invitation via email to participate in a survey to 35 
registered nurses who completed the APHON chemotherapy/biotherapy provider course as of 
April 2014. The email explained the purpose of the study and contained an anonymous link to 
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the Qualtrics survey. Completion of the survey was completely voluntary and in no way affects 
the participant’s employment or performance evaluation as the PI does not supervise or evaluate 
any of the registered nurses. The survey was available for approximately two weeks, with a 
reminder email being sent to subjects after the survey had been open for one week.  
Design 
 A cross-sectional, descriptive design was used in the twenty-six item questionnaire 
developed by the PI (Appendix C). The first five questions of the survey were related to 
demographics. Questions six through twenty-four asked participants to rate their knowledge of 
and confidence in administering chemotherapy using a Likert-type scale. The last two questions 
in the survey allowed for participants to articulate their experiences as APHON 
chemotherapy/biotherapy providers. According to DeVellis (2012) the Cronbach alpha 
coefficient of a scale should be above 0.7. The survey demonstrates good internal consistency 
with a Cronbach alpha coefficient of 0.84. The introductory email informed participants of no 
more than minimal risk involved in completing the survey, indicated consent by participating in 
the study, contained an anonymous link to the Qualtrics survey, and contained contact 
information for the PI as well as the University of Kentucky Office of Research Integrity. 
Participants could discontinue the survey at any point.  
Outcome Measures 
 Pediatric oncology nurses’ knowledge of and confidence in administration of 
chemotherapy were measured with a four-point, Likert-type scale with a total scale score of 
seventy-six. Correlation analysis was used to determine if there is a linear relationship between 
participants’ ages and total score. Additionally, bivariate analysis was used to determine if 
participants’ overall scores are related to education level and analysis of variance was used to 
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compare overall scores with years of pediatric oncology nursing experience as well as number of 
months the nurse has held the APHON provider status. The two open response questions at the 
end of the survey were intended to gain insight into the nurses’ experiences as APHON 
chemotherapy/biotherapy providers.  
Statistical Analysis 
 Descriptive statistics including means, medians and standard deviations were used. Data 
were analyzed using SPSS version 22.0 with a significance set at p < 0.05 for all results. Pearson 
product-moment correlation coefficient was used to determine if there was a relationship 
between participants’ ages and overall score. Since the scores from the nineteen Likert-type 
questions followed a normal distribution, it was appropriate to perform parametric tests to 
determine whether there were statistically significant differences among groups. An 
independent-sample t-test was used to determine if there was a significant difference in the total 
score for associate degree nurses compared to nurses who have a bachelor’s degree or higher. 
Finally, one-way analysis of variance (ANOVA) was used to determine if there was a difference 
in overall score related to 1.) experience as a pediatric oncology nurse measured in years or 2.) 
number of months participants have held the APHON provider status.  
Study Results 
 A total of twenty-five (n=25) nurses completed the survey. Demographic data are 
presented in Table 1. Twenty-four of the twenty-five respondents were female. The mean age of 
participants was 37.6±8.7 years. The mean score from the 19 Likert-type questions was 69.2, 
with a median of 69, and a range of 59-76. There was a small, positive correlation with age of 
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participants and overall score (r = 0.11, p = 0.59). There was no significant difference in overall 
score related to academic degree level of respondents (p =0.79), number of years of experience 
(p =0.94), or number of months participants held the APHON provider status (p =0.12). Twenty 
three of the 25 (92%) participants strongly agreed that they have a personal responsibility for the 
safe administration of chemotherapy/biotherapy agents to pediatric oncology patients and that 
the RN is a critical final check prior to administration. Nearly all participants (96%) reported 
feeling confident in their ability to independently calculate a patient’s body surface area (BSA) 
and verify an ordered chemotherapy/biotherapy dose based on the BSA. 
 Seventeen participants (68%) strongly agreed that continuing education related to 
reinforcement of knowledge related to safe administration of chemotherapy/biotherapy to 
pediatric oncology is important, while fourteen nurses (56%) strongly agreed that becoming an 
APHON chemotherapy/biotherapy provider has stimulated their interest in pursuing specialty 
certification as a certified pediatric hematology/oncology nurse (CPHON). Nearly all nurses 
(88%) reported ensuring a treatment roadmap accompanied a chemotherapy/biotherapy order 
every time. Additionally, all nurses (100%) reported they always double check 
chemotherapy/biotherapy doses with a second RN and if there is a question regarding the 
chemotherapy/biotherapy dose, they contact the nurse practitioner or attending physician for 
clarification; however, when asked specifically the level of comfortability one had in challenging 
a chemotherapy/biotherapy order they believed to be incorrect, only 16 (64%) of participants 
reported feeling comfortable. 
In the open response portion of the survey, two nurses reported finding incorrect doses  
during the dose verification process  (independent calculation of BSA and dose) and notified the 
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attending physician while others described being able to recognize side effects of drugs that they 
were unaware of prior to completing the APHON course. Furthermore, nurses reported feeling 
more confident in their ability to answer patients’ and families’ questions regarding drugs/side 
effects following completion of the APHON course.  
Discussion 
 The high mean score of participants on the Likert-type questions indicates nurses feel 
knowledgeable regarding administration of chemotherapy and biotherapy to pediatric oncology 
patients and are confident in their ability to educate patients and families. The study revealed no 
significant statistical difference in overall score related to participant age, education level, nor 
amount of time the participant has held the APHON provider status. While the majority of 
respondents reported always following the APHON guidelines for safe administration of 
chemotherapy and biotherapy, 12% of participants reported ensuring the patient’s roadmap 
accompanied the chemotherapy order most of the time. It would be interesting to know the 
reasons why this is not the case all of the time and further investigation into why this is not the 
standard practice 100% of the time is warranted. Furthermore, it is worth following up with 
nurses regarding their level of comfortability in challenging a chemotherapy/biotherapy order 
they believed to be incorrect. Perhaps reinforcing the notion that it is always acceptable to notify 
an attending or advanced practice nurse if there is question regarding a chemotherapy order 
would be beneficial. 
 The results of this study indicate the majority of participants are interested in continuing 
education related to safe administration of chemotherapy and biotherapy to pediatric patients 
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with 56% of participants indicating an interest in obtaining specialty certification. Planning is 
underway for a CPHON review course for nurses as a result of this feedback.  
 In the open response portion of the survey, participants were asked to describe a patient 
encounter in which he/she was totally confident in the decision made and how the knowledge 
obtained in the APHON course guided the decision. Of particular interest were the responses in 
which nurses recalled specific instances in which they caught an incorrect chemotherapy dose 
while independently calculating the patient’s BSA against the ordered dose and appropriately 
notified the attending physician. Retrospectively, it would have been nice to know whether or not 
there was a difference in chemotherapy error rates (dose calculation or administration error) prior 
to implementation of the APHON program compared to points in time following 
implementation.  
Limitations 
 Results of the study cannot be generalized due to the small sample size. No standardized 
questionnaire exists to address the aims of the study and a review of the literature did not reveal 
comparable studies. Although participation in the study was completely voluntary and in no way 
affected employment or performance evaluations, recall and self-report bias may have influenced 
the results. It should also be noted that a knowledge assessment regarding safe administration of 
chemotherapy was performed prior to implementation of the APHON course; however, this 
study was not planned at that time and IRB approval was not obtained for that assessment. The 
results of that assessment determined the need for a future educational intervention as several 
knowledge gaps were revealed and the PI was interested in specific administration procedures in 
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the post evaluation. Data regarding chemotherapy administration errors prior to and after 
implementation of the APHON course would have also enriched the study.  
Conclusion 
 Evaluation of the APHON chemotherapy/biotherapy program at least one year post 
participants’ completion revealed high scores related to knowledge regarding safe administration 
of antineoplastic agents to pediatric oncology patients. Data analysis revealed the desire for 
continuing education as well as interest in specialty certification, both of which will enrich 
nursing practice. It is encouraging to know that the majority of the time nurses are following the 
APHON standards for safe administration of chemotherapy; however, it should be reinforced 
that the standards apply to every patient, every time an antineoplastic agent is administered.  
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Table 1. Demographic characteristics of study nurses (N = 25) 
 
Variable  
 
 
Mean (SD) or n (%) 
 
Age 
 
 
37.6±8.7 years 
Gender 
   Male 
   Female 
 
1(4%) 
24(96%) 
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Table 2. Bivariate associations among continuous demographic characteristics and knowledge 
 
Variable 
 
r 
 
 
p 
 
Age 
 
 
0.11 
 
0.59 
…   
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Table 3. Bivariate associations among categorical demographic characteristics and knowledge 
 
Variable 
 
Mean (SD) 
 
 
t (p) 
 
Nursing degree 
   ADN 
   BSN/MSN 
 
 
 
68.41(4.87) 
                 69.92(4.7) 
 
 
0.79(0.44) 
 
Years of experience as a pediatric 
Oncology nurse 
 
   1-5 years              68.33(4.72)                                         0.06(0.94) 
 
   6-10 years                                                       69(5.24) 
 
   >10 years                                                        69.2(4.54) 
 
 
 
Amount of time participant has 
held APHON provider status 
 
   12-15 months                                                  66.14(5.61)                                        2.3(0.12)    
 
   16-18 months                                                  69.8(1.92) 
 
   >18 months                                                     70.62(4.5) 
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Practice Inquiry Report Conclusion 
Because of its high-alert status, it is imperative that all nurses who administer 
chemotherapy and biotherapy to pediatric oncology patients have the knowledge base needed to 
ensure safe administration with every patient, every time so potentially harmful errors can be 
avoided. The literature acknowledges the importance of adherence to guidelines when 
administering chemotherapy and biotherapy to pediatric oncology patients and this practice 
inquiry project sought to improve the knowledge base of pediatric oncology nurses regarding 
safe administration of chemotherapy and biotherapy to pediatric oncology patients through 
implementation of the APHON Chemotherapy/Biotherapy provider course. Subsequent 
evaluation was performed to assess nurses’ knowledge and beliefs related to 
chemotherapy/biotherapy administration at least one year post implementation of the APHON 
chemotherapy/biotherapy provider course revealing high scores related to knowledge concerning 
safe administration of neoplastic agents to pediatric oncology patients. Furthermore, data 
analysis revealed the desire for continuing education as well as interest in specialty certification, 
which has led to planning for a CPHON review course available in the fall of 2015. 
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Appendix A.  Approval Letter from Institutional Review Board 
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Appendix B. Survey Invitation Email 
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Appendix C.  Survey 
 
What is your gender? 
Male 
Female 
 
What is your age in years? 
______ 
 
What is your highest nursing degree? 
ADN 
BSN 
MSN 
DNP 
PhD in nursing 
 
How many years of experience do you have as a pediatric oncology nurse? 
Less than 1 year 
1-5 years 
6-10 years 
Greater than 10 years 
 
How long have you held the APHON chemotherapy/biotherapy status? 
12-15 months 
16-18 months 
More than 18 months 
 
Please rate the degree to which you agree or disagree with the following statements.  
I am comfortable reviewing and understand Children’s Oncology Group (COG) roadmaps. 
Strongly Disagree 
Disagree 
Agree  
Strongly Agree 
 
I believe that as an RN I play a crucial role in educating my patients and families regarding the 
side effects of specific chemotherapy/biotherapy agents. 
Strongly Disagree 
Disagree 
Agree  
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Strongly Agree 
 
I believe the RN is a critical final check prior to safely administering chemotherapy/biotherapy 
agents. 
Strongly Disagree 
Disagree 
Agree  
Strongly Agree 
 
I feel a strong personal responsibility for the safe administration of chemotherapy/biotherapy 
agents to pediatric oncology patients. 
 
Strongly Disagree 
Disagree 
Agree  
Strongly Agree 
 
I am confident in my ability to educate patients and families regarding the side effects of specific 
chemotherapy/biotherapy agents.  
 
Strongly Disagree 
Disagree 
Agree  
Strongly Agree 
 
I understand the importance of patients’ participation in clinical trials as part of the COG 
research cooperative. 
 
Strongly Disagree 
Disagree 
Agree  
Strongly Agree 
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I believe the RN plays an important role in facilitating patients’ participation in COG clinical 
trials. 
 
Strongly Disagree 
Disagree 
Agree  
Strongly Agree 
 
I believe it is critical to review the patients’ roadmaps prior to administering any 
chemotherapy/biotherapy. 
 
Strongly Disagree 
Disagree 
Agree  
Strongly Agree 
 
I am confident in my ability to independently calculate a patient’s body surface area (BSA) and 
verify chemotherapy/biotherapy doses based on the BSA. 
 
Strongly Disagree 
Disagree 
Agree  
Strongly Agree 
 
I am confident in my ability to recognize and mange toxicities related to 
chemotherapy/biotherapy agents in pediatric oncology patients. 
 
Strongly Disagree 
Disagree 
Agree  
Strongly Agree 
 
I am familiar with the appropriate chain of command to whom I can address questions or 
concerns regarding chemotherapy/biotherapy agents. 
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Strongly Disagree 
Disagree 
Agree  
Strongly Agree 
 
I am comfortable challenging a chemotherapy/biotherapy order I believe is incorrect. 
 
Strongly Disagree 
Disagree 
Agree  
Strongly Agree 
 
I feel valued as a professional member of the pediatric oncology healthcare team. 
 
Strongly Disagree 
Disagree 
Agree  
Strongly Agree 
 
I am confident in my ability to safely administer chemotherapy/biotherapy to pediatric oncology 
patients. 
 
Strongly Disagree 
Disagree 
Agree  
Strongly Agree 
Please rate the degree to which you do or do not do the following.  
I ensure the roadmap accompanies the chemotherapy/biotherapy order. 
All of the time 
Most of the time 
Never 
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I double check the chemotherapy/biotherapy doses with another RN. 
 
All of the time 
Most of the time 
Never 
If there is a question regarding a chemotherapy/biotherapy dose or start time, I contact the nurse 
practitioner or attending physician. 
All of the time 
Most of the time 
Never 
 
The following questions will allow you the opportunity to tell us more about your experience as 
an APHON chemotherapy/biotherapy provider. 
  
Please describe how becoming an APHON chemotherapy/biotherapy provider has made you a 
more confident nurse. 
  
  
Now that you are an APHON chemotherapy/biotherapy provider, you have the knowledge to be 
more confident in the care you provide. Please share a story regarding a specific patient 
encounter (do not give names or identifiers) in which you felt totally confident in the decisions 
you made and the care you provided. Be specific regarding how the knowledge obtained in the 
APHON course guided the care you provided. Do not be humble.  
 
Thank you for completing the survey. 
You may direct questions or complaints regarding this survey to the principal investigator, 
Leslee Bertram, at leslee.bertram@uky.edu   
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